Compare spironolactone vs eplerenone for heart failure patients
Treatments studied
Part of Heart & circulation clinical trials.
This study uses Denmark’s heart failure registry to compare two common tablet medicines—spironolactone and eplerenone—for people with symptomatic systolic heart failure. It aims to see which one leads to better health outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are listed in the Danish Heart Failure Registry
- Your heart function test shows left ventricular ejection fraction under 40%
- You recently filled a prescription for an “aldosterone antagonist” (either spironolactone or eplerenone)
- You had not filled an aldosterone antagonist prescription before being registered in the registry
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two heart medicines, carvedilol and metoprolol succinate, for people with a certain type of heart failure. It aims to see if they work just as well as each other.
This trial tests whether starting spironolactone helps people with heart failure symptoms when the heart pumps “preserved” (not severely reduced). Participants are assigned to start spironolactone or usual care so researchers can see if it improves outcomes.
This study compares two medicines, spironolactone and finerenone, to see which one manages potassium levels better in people with heart failure, type 2 diabetes, and kidney disease. Participants have high potassium levels, and the trial aims to find a safer way to manage this.
This trial compares two medicines, finerenone and spironolactone, to see which works better and is safer for lowering blood pressure in people with primary aldosteronism. It may help you if you have high blood pressure caused by too much aldosterone.
This Phase 2 study tests whether eplerenone can improve outcomes after a heart attack (or similar heart injury) when coronary angiography shows no blocked heart arteries. It focuses on people with added cardiovascular risk factors and evaluates how well the treatment works for heart recovery and strain on the heart.
This study looks at how primary aldosteronism affects the heart and blood vessels, and whether blocking its hormone signal (with spironolactone or eplerenone) changes those findings on imaging tests. It is small and focuses on people with confirmed or suspected primary aldosteronism who are being followed for heart health.
Hear when a new Systolic Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.